Rubicon Research Share News - Latest Updates, Live News & More

Latest news about Rubicon Research

USFDA Conducts Unannounced Inspection of Rubicon Research's Pithampur Facility, Issues Form 483 With 2 Observations 10 days ago

The USFDA conducted an unannounced inspection of Rubicon Research's Pithampur facility from June 29 to July 3, 2026. The inspection concluded with the issuance of a Form 483 containing 2 observations. Importantly, no data integrity issues were identified during the inspection, marking a significant aspect of the regulatory review outcome.

Rubicon Research Q4FY26 revenue rises 44% to ₹5,140 million Jun 03, 2026

Rubicon FY26 net profit rises 84% to ₹2.47 billion May 31, 2026

Rubicon Research approves ESOS 2026 for 24.84 lakh options May 30, 2026

Rubicon Research Limited Completes 85% Stake Acquisition in Arinna Lifesciences Limited May 02, 2026

More news about Rubicon Research

25Apr 26

Rubicon Research Limited Successfully Completes USFDA Inspection at Canada R&D Facility Without Form-483

Rubicon Research Limited announced successful completion of an unannounced USFDA inspection at its R&D facility in Concord, Ontario, Canada, conducted from April 20-24, 2026. The inspection concluded without any Form-483 being issued, indicating full compliance with FDA regulatory standards. The company formally communicated this positive outcome to BSE Limited and National Stock Exchange of India Limited through an official disclosure signed by Company Secretary Deepashree Tanksale under SEBI Regulation 30.

23Apr 26

Rubicon Research Receives ₹17.25 Crore Income Tax Demand for AY 2023-24

Rubicon Research Limited disclosed receiving an Income Tax Assessment Order for AY 2023-24 with a demand of Rs. 17,25,17,210 related to Arms' Length Pricing adjustments on international transactions. The company has also received a show cause notice for penalty proceedings and is preparing to file an appeal while expressing confidence in its position.

16Apr 26

Rubicon Research Acquires 85% Stake in Arinna; Motilal Oswal Raises Target to ₹955

Rubicon Research Limited has officially announced the acquisition of an 85% equity stake in Arinna Lifesciences Limited for INR 175.92 crores, marking its strategic entry into the Indian CNS formulations market. Arinna, with over 60 brands and 4,000+ prescriber relationships, reported revenue of INR 56.70 crores and EBITDA of INR 9.50 crores for the 9 months ended December 2025. Motilal Oswal maintains Buy rating while raising the target price to ₹955, citing strategic benefits from the acquisition.

13Apr 26

Rubicon Research Limited Receives SEBI Compliance Certificate for Q4FY26

Rubicon Research Limited received a quarterly compliance certificate from MUFG Intime India Private Limited for Q4FY26, confirming adherence to SEBI dematerialisation regulations. The certificate, issued on April 3, 2026, verifies proper processing of securities and compliance with prescribed timelines. Company Secretary Deepashree Tanksale filed the certificate with BSE and NSE on April 13, 2026, fulfilling regulatory obligations.

01Apr 26

Rubicon Research Limited Allots 3,41,815 Equity Shares Under Employee Stock Option Scheme

Rubicon Research Limited allotted 3,41,815 equity shares on March 31, 2026, under its Employee Stock Option Scheme 2022, with approval from the Nomination and Remuneration Committee. The allotment increased the company's paid-up equity share capital to ₹16,50,92,124, comprising 16,50,92,124 shares of ₹1 face value each. The company informed both BSE and NSE about this development in compliance with SEBI regulations.

16Mar 26

Rubicon Research Limited Declares Postal Ballot Results with Strong Shareholder Participation

Rubicon Research Limited declared postal ballot results on 16th March 2026, with both resolutions receiving shareholder approval through remote e-voting. The process witnessed 75.95% participation from 30,072 members holding 16,47,50,309 equity shares, with SGGS & Associates serving as scrutinizer and MUFG Intime as the electronic voting service provider.

13Feb 26

Rubicon Research Limited Announces Postal Ballot for Independent Director and Secretarial Auditor Appointments

Rubicon Research Limited has issued a postal ballot notice for two key appointments: Dr. Pradnya Saravade as Independent Woman Director and M/s. BNP & Associates as Secretarial Auditors. The e-voting period runs from February 14-March 15, 2026, with results expected by March 17, 2026. Dr. Saravade brings extensive governance experience from her career in Indian Police Service, SEBI, and CBI, while the secretarial audit appointment ensures compliance with listing regulations following the company's recent IPO in October 2025.

06Feb 26

Rubicon Research Q3 Net Profit Jumps 91% to ₹728M; Management Confident on Growth

Rubicon Research delivered strong Q3 FY26 performance with net profit surging 91% to ₹73 crores and revenue growing 52% to ₹476 crores. The company's R&D productivity has improved significantly, with investment returns increasing from 3.3x to 5.7x over rolling periods. Management remains confident about growth trajectory, maintaining EBITDA margin guidance of 22%-23% while progressing with Pithampur facility operationalization expected by mid-2026.

03Feb 26

Rubicon Research Board Meeting Outcome: Director Changes & Subsidiary Merger

Rubicon Research Limited conducted a comprehensive board meeting on February 3, 2026, addressing multiple governance and strategic matters. The board approved the appointment of Dr. Pradnya Saravade, a former IPS officer with extensive SEBI and CBI experience, as Additional Independent Woman Director for three years, while noting the resignation of Mr. Anand Agarwal as Non-Executive Director. Additionally, the board appointed M/s. BNP & Associates as Secretarial Auditor for a five-year term and granted in-principle approval for merging wholly-owned subsidiary KIA Health Tech Private Limited to achieve operational synergies.

30Jan 26

Rubicon Research Limited Reports GST Inspection at Thane and Ambernath Offices

Rubicon Research Limited reported that GST authorities initiated inspection proceedings at its Thane and Ambernath offices on January 30, 2026, under Section 67 of the Maharashtra GST Act. The company is providing full cooperation to officials while business operations continue normally. Based on initial assessment, no material impact on financials or operations is expected from these proceedings.

27Jan 26

Rubicon Research Limited Schedules Board Meeting on February 3, 2026 for Q3FY26 Financial Results

Rubicon Research Limited has scheduled a board meeting for February 3, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The announcement was made on January 27, 2026, in compliance with SEBI Regulation 29. The company has implemented trading window restrictions from January 1, 2026, which will remain in effect until 48 hours after the financial results announcement, as part of its insider trading prevention measures.

13Jan 26

Investec Initiates Buy Rating on Rubicon Research with ₹820 Target Price, Projects 47% EPS CAGR

Investec has initiated buy coverage on Rubicon Research with a ₹820.00 target price, projecting 47% EPS CAGR between FY25-FY28. The brokerage highlights the company's ROI-driven strategy achieving over 25% returns and transformation into a specialty-led pharma player. Specialty Generics segment is expected to drive growth with over 10 upcoming launches, increasing gross profit share from 33% to 45-50%.

09Jan 26

Rubicon Research Limited Appoints Ms. Avani Harish Shah as General Manager for Legal and Compliance

Rubicon Research Limited appointed Ms. Avani Harish Shah as General Manager – Secretarial, Legal & Compliance, effective January 9, 2026. Shah brings over 20 years of corporate legal experience from the IT services industry, including senior roles at LTIMindtree Limited, Capgemini Technologies, and other major corporations. She holds advanced legal qualifications with specialization in Intellectual Property Rights from Government Law College, Mumbai.

06Jan 26

Rubicon Research Subsidiary AdvaGen Pharma Receives ₹4.19 Crore Tax Demand Notice

Rubicon Research Limited's material subsidiary AdvaGen Pharma Ltd received a ₹4.19 crore tax demand notice from Mumbai Income Tax authorities for assessment year 2021-22. The demand arises from denial of DTAA exemption on ₹10.04 crore income under India-US tax treaty. The subsidiary plans to appeal before ITAT while seeking a stay on the demand, with the company expressing confidence in its legal position.

08Dec 25

Rubicon Research Limited Shareholders Approve All Six Resolutions in Postal Ballot

Rubicon Research, a pharmaceutical company, announced that its shareholders have approved all six resolutions proposed in a recent postal ballot. The voting, which concluded on December 7, 2025, was conducted through remote e-voting. Shareholder support ranged from 88.81% to 95.18% in favor of the resolutions. The approved resolutions included a promoter agreement and ratification of employee stock option plans. This strong support indicates confidence in the company's management and strategic direction.

13Nov 25

Rubicon Research Reports Strong Q2 Growth with 56% Jump in Net Profit

Rubicon Research Limited posted strong Q2 FY2026 results with net profit up 56.2% to 539 million rupees and revenue rising 39.2% to 4.12 billion rupees. EBITDA grew 52.9% to 943 million rupees with margin improving to 22.9%. The company's product diversification strategy showed progress with top 5 products now contributing 30% of revenue, down from 34% in Q1. R&D expenses were 11.2% of operating revenue at 475.89 million rupees. Rubicon plans to operationalize its Pithampur plant in mid-2026 to address capacity constraints. The company maintains a strong financial position with 1,514 million rupees in cash and cash equivalents.

13Nov 25

Rubicon Research Reports Insider Trading Violations, Issues Warnings

Rubicon Research Limited disclosed two cases of insider trading violations. The first involved VP Amol Shamrao Masal selling 30 shares on October 28, 2025, violating contra trade rules and trading window closure. The second case involved HR Head Romola Pinto and relative Vikram N Pinto acquiring 20 shares on October 16, 2025, during a closed trading window. Both trades were deemed inadvertent and of insignificant amounts. The company issued warning letters to the parties involved and reported the incidents to stock exchanges in compliance with SEBI regulations.

Rubicon Research

1,438.20

+6.80

(+0.48%)

1 Year Returns:+128.94%

Industry Peers

Sun Pharmaceutical

1,921.40

(-0.73%)

Divis Laboratories

6,938.50

(+1.50%)

Torrent Pharmaceuticals

4,951.10

(+1.01%)

Cipla

1,426.70

(-0.88%)

Lupin

2,492.60

(-0.15%)

Zydus Life Science

1,131.30

(-1.69%)

Mankind Pharma

2,507.50

(-0.70%)

Dr Reddys Laboratories

1,234.50

(-0.79%)

Aurobindo Pharma

1,549.30

(-0.98%)

Laurus Labs

1,558.60

(+1.35%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104